

1 **Original article**

2 **Title: Prevalence of neutralizing antibody to human coronavirus 229E in Taiwan**

3 Hao-Huan Chen¹, Wei-Fan Chen¹, Yhu-Chia Hsieh^{2,3}, Chih-Jung Chen^{2,3,4*}

4

5 ¹Taipei Municipal Jianguo High School, 100 Taipei, Taiwan

6 ²Division of Pediatric Infectious Diseases, Departments of Pediatrics, Chang Gung Memorial

7 Hospital, 333 Taoyuan, Taiwan

8 ³School of Medicine, College of Medicine, Chang Gung University, 333 Taoyuan, Taiwan

9 ⁴Molecular Infectious Diseases Research Center, Chang Gung Memorial Hospital, 333 Taoyuan,

10 Taiwan

11 Wei-Fan Chen and Hao-Huan Chen contributed equally to this study

12 **Running title:** Seroprevalence of HCoV-229E

13 ***Corresponding author:** Dr. Chih-Jung Chen, Department of Pediatrics, Chang Gung Memorial

14 Hospital, No, 5, Fu-Shin St., Kweishan, Taoyuan County 333, Taiwan

15 Tel: 886-3-3281200 ext. 8202; Fax: 886-3-3288957

16 E-mail: chinjung@cgmh.org.tw; james.ped@gmail.com

17

18

19

20

21 **ABSTRACT**

22 **Background** Four members in the Coronaviruses family including 229E circulating in the
23 community were known to cause mild respiratory tract infections in humans. The epidemiologic
24 information of the seasonal human coronavirus (HCoV) may help gain insight into the development
25 of the ongoing pandemic of coronavirus disease since 2019 (COVID-19).

26 **Methods** Plasma collection containing 1558 samples was obtained in 2010 for an estimate of the
27 prevalence and severity of 2009 pandemic influenza A H1N1 in Taiwan. Of 1558 samples, 200
28 were randomly selected from those aged < 1 year to > 60 years. The neutralizing antibody titers to
29 HCoV-229E were determined in the serums using live virus ATCC® VR-740™ cultivating in the
30 Huh-7 cell line.

31 **Results** Seroconversion of HCoV-229E (titer \geq 1:2) was identified as early as less than 5 years of
32 age. Among 140 subjects aged younger than or equal to 40 years, all of them had uniformly low
33 titers (< 1:10) and the geometric mean titers (GMTs) were not significantly different for those aged
34 0-5, 6-12, 13-18 and 19-40 years ($P > 0.1$). For 60 subjects greater than 40 years old, a majority (39,
35 65%) of them had high titers \geq 1:10 and the GMTs were significantly increased with advanced age
36 ($P < 0.0001$). Age was the most significant factor predicting seropositivity in the multivariate
37 analysis, with an adjusted odds ratio of 1.107 and a 95% adjusted confidence interval of
38 1.061–1.155 ($P < 0.0001$).

39 **Conclusion**

40 HCoV-229E infection occurred as early as younger than 5 years old in Taiwanese and the
41 magnitudes of neutralizing titers against HCoV-229E increased with advanced age beyond 40 years.
42

43 INTRODUCTION

44 Coronaviruses are positive-sense, single-stranded RNA viruses, causing respiratory or intestinal
45 infections in human beings and/or animals.¹ They are named for the crown-like appearance under
46 an electron microscope. Before the emergence of SARS-CoV-2 responsible for the ongoing global
47 pandemic of coronavirus disease 2019 (COVID-19), six coronaviruses had been known to cause
48 distinct respiratory syndromes in humans. Four of the human coronaviruses (HCoVs), namely
49 HCoV-229E, HCoV-OC43, HCoV-NL63 and HCoV-HKU1, were seasonal organisms circulating
50 in the community and typically associated with mild and self-limited respiratory tract infections in
51 children.² The other two species including Severe Acute Respiratory Syndrome coronavirus
52 (SARS-CoV-1) and Middle East Respiratory Syndrome coronavirus (MERS-CoV) were of greater
53 virulent potential especially in adult populations and accounted for the epidemics of lethal
54 respiratory diseases in 2002 and 2013, respectively.³

55 It has been suggested that the first seasonal HCoVs infections generally occurred in early
56 childhood and repeated infections with the same virus was frequently identified throughout the
57 whole life.^{1,2,4} However, the infections of seasonal HCoVs appeared to vary substantially across
58 different age groups and in distinct geographic regions. In Taiwan, the HCoV-NL63 was detected in
59 1.3% of hospitalized children with respiratory tract infections in northern Taiwan during 2004 and
60 2005 whereas 8.4% of hospitalized patients of all ages with pneumonia in central Taiwan during
61 2010 and 2011 were associated with this organism.^{5,6} The epidemiologic information of other three
62 seasonal HCoVs were completely lacking in this island. To better understand the epidemiology of

63 seasonal HCoV, we conducted a seroprevalence study by measuring the neutralizing antibody
64 (NAb) titers against the HCoV-229E among different age groups of Taiwanese population.

65 **METHODS**

66 *Subjects*

67 The serum samples were selected from the plasma collection containing 1558 samples obtained in
68 2010, which had been used to estimate the prevalence and severity of 2009 pandemic influenza A
69 H1N1 in the general population in Taiwan.⁷ For this study, the participants were categorized by
70 ages into different groups respectively of age 0 – 5 years, 6 – 12 years, 13 – 18 years, 19 – 60 years
71 and > 60 years. Random samples with indicated numbers as shown in Table 1 were selected from
72 each age group and determined for NAb titers against HCoV-229E virus. The study was approved
73 by the institute review boards in Chang Gung Memorial Hospital (202100266B0). A waiver of
74 informed consent was granted given the retrospective nature of the project and anonymous analysis of
75 the samples and the demographic information.

76 *Neutralization assay*

77 The Huh-7 cell line (JCRB0403) was obtained from Japanese Collection of Research Bioresources
78 Cell Bank and grown in low glucose Dulbecco's modified Eagle medium (LG-DMEM, Gibco)
79 supplemented with 10% heated inactivated fetal bovine serum (FBS, Biological Industries) and 1%
80 penicillin/streptomycin (P/S, Biological Industries) at 37°C, 5% CO₂. HCoV-229E (ATCC®
81 VR-740™) was cultivated in the same medium but with the FBS concentration reduced to 2% at
82 35°C at 5% CO₂. The virus was propagated and quantified in Huh-7 cells by measuring the 50%

83 tissue culture infective dose (TCID₅₀). For neutralization test, sera were serially two-fold diluted in
84 the same medium as used for the virus culture, and mixed 1:1 with HCoV-229E (2000 TCID₅₀/mL)
85 in 96-well-plate. The plates then were incubated at 35 °C and 5% CO₂ for 2h before addition of
86 Huh-7 cells to the mixtures. The result of the virus infection was determined after 5 days of
87 incubation. All sera were previously inactivated at 56 °C for 30 min. A titer of $\geq 1:10$ was defined as
88 high titer. Comparison of categorical variables between seronegative and seropositive groups was
89 performed with a chi-square test or with the Fisher exact test where appropriate, whereas
90 differences among the numerical variables were analyzed by two-sample t-test. The general linear
91 model (GLM) procedure was used for comparison of geometric mean titers (GMT) between age
92 groups. Multiple logistic regression analysis was applied to explore factors associated with high
93 NAb titers $\geq 1:10$. Statistic significance was defined as a P value of <0.05 in the tests. The statistics
94 were performed using an SAS 9.3 for windows (SAS Institute, Inc., Cary, NC).

95 **RESULTS**

96 The distribution of NAb titers against HCoV-229E in 200 participants at different ages is
97 shown in Figure 1A. The comparisons of different age groups regarding to the GMTs of NAb is
98 displayed in Figure 1B. Among 140 participants aged younger than or equal to 40 years, all of them
99 had uniformly low titers ($< 1:10$, Figure 1A) and the GMTs were not significantly different for
100 those aged 0-5, 6-12, 13-18 and 19-40 years ($P > 0.1$ for all pairwise comparisons by GLM). On the
101 contrary, for 60 participants greater than 40 years old, a majority (39, 65%) of them had high titers
102 $\geq 1:10$ and the GMT were significantly increased in participants aged 41-60 years when compared

103 to the younger participants aged 19-40 years (1.57 versus 4.58, $P < .0001$). The GMT level further
104 elevated significantly in the participants aged > 60 years (Figure 1B).

105 To determine the factors associated with elevated NAb titers, we compared a variety of
106 demographic and clinical parameters between the participants by an arbitrarily defined NAb titer
107 cut-off of 1:10. When compared to the participants with low titers ($< 1:10$), the participants with
108 high titers $\geq 1:10$ were at significantly elder age (64.3 ± 9.59 years versus 17.9 ± 18.0 years, $P <$
109 0.0001 , Table 1). In addition to the age factor, the living areas, number of family members, certain
110 co-morbidities including heart diseases and metabolic disorders, and the seropositivity of pandemic
111 influenza H1N1 in 2009 were also significant parameters of participants associated with high NAb
112 titers in the univariate analysis (Table 1). However, a majority of the parameters lost their
113 significance in the multivariate logistic regression analysis. The age remained the most significant
114 factor in the multivariate analysis, with an adjusted odds ratio of 1.107 and a 95% adjusted
115 confidence interval of 1.061–1.155 ($P < 0.0001$, Table 1).

116 **DISCUSSION**

117 Results from the current study indicated that the age was a significant, if not the only, factor
118 associated with NAb titers against HCoV-229E in Taiwan. It was intriguingly to learn that the NAb
119 titers increased with advanced age, though commenced at young adults, did not reach a significant
120 level until the age of or greater than 40 years old (Figure 1B). The result was inconsistent with the
121 finding of other studies with similar design, which usually disclosed incremental seropositive rates
122 in childhood until a plateau commencing in young adulthood.^{1,9} Ethnic and geographic factors

123 might both be implicated in the discrepant results in the current and others' studies. Further, the
124 seropositivity was substantially influenced by the sensitivities of different antibody detection
125 methods. Indeed, the detection rates of NAb against HCoV-229E were usually much lower compared to
126 those determined by the enzyme immunoassay (EIA) methods.^{1,8} No standard method measuring
127 the NAb titers, use of different targets in EIA methods, and no consensus defining seropositivity
128 further complicated the interpretation of the seroprevalence studies. Nevertheless, our study clearly
129 demonstrated the HCoV-229E infection, when defined by a cut-off titer of $\geq 1:2$, occurred as early
130 as at 0 – 5 years of age. Before entering into adulthood, at least 17.5% of Taiwanese have been
131 infected with this viral agent and 90% of population had been infected at least once throughout the
132 life. The data indicated that the exposure to HCoV-229E was common in Taiwanese population of
133 all ages irrespective of gender and other demographic characteristics.

134 The NAb titers against HCoV-229E were at exclusively low levels ($< 1:10$) in participants
135 younger than 40 years of age. On the contrary, a majority of the cases equal or elder than 40 years
136 of age had high levels of NAb. Of note, the proportions of cases with NAb titer $\geq 1:10$ was 45%
137 (9/20) in participants aged 40 – 60 years and increased to 75% (30/40, Table 1) in those elder than
138 60 years old. The observation might suggest a relatively poor humoral immune response evoked by
139 HCoV-229E infections in young populations. The significant elevation of NAb titer in middle age
140 was likely caused by a more potent or accumulated humoral immunity possibly due to the amnestic
141 response of repeated infections with HCoV-229E. The speculation was supported by a 35-year
142 longitudinal serosurvey investigating the change of antibody titers to HCoVs in 10 individuals in

143 Amsterdam, which demonstrated that the reinfections with the same HCoV strains indicated by
144 abrupt elevation of antibody titer were common events in adult individuals.⁴

145 In coincidence with the elevated NAb titers against HCoV-229E in middle age group and
146 elderly, the COVID-19 severity increased significantly in patients beyond 40 years of age. It was
147 suggested that various immune dysregulations were implicated in the severe lung disease of
148 COVID-19. Indeed, an machinery called antibody-dependent enhancement (ADE) was among the
149 potential mechanisms accounting for the enhanced respiratory diseases of COVID-19.⁹ The
150 speculation was supported by the 1-week delayed development of severe respiratory symptoms
151 during the course of COVID-19.¹⁰ The presence of non-neutralizing antibody during infection has
152 been shown to enhance virus infection, induce uncontrolled cytokine release and Th2
153 hyperinflammation in the airway with SARS-CoV-1 and MERS-CoV infections. The high antibody
154 titers evoked by the common seasonal HCoV infections including HCoV-229E might play a
155 contributing role to the greater morbidity and mortality of COVID-19 in patients with advanced
156 ages. Further studies investigating into the interaction between immune profiles of the seasonal
157 HCoVs and SARS-CoV-2 infection might help get insight into the pathogenesis of COVID-19.

158 In conclusion, the seroconversion of HCoV-229E in Taiwanese occurred early in childhood
159 younger than 5 years of age. Both the positive rates of NAb and magnitude of NAb titers to
160 HCoV-229E increased when the age advanced. The high NAb titer $\geq 1:10$ was exclusively
161 identified in middle age group and elderly who were coincidentally vulnerable to severe COVID-19
162 diseases.

163 **ACKNOWLEDGMENTS**

164 We thank Dr. Shin-Ru Shih, Director in Research Center for Emerging Viral Infections in Chang
165 Gung University, Taiwan, for providing the HCoV-229E virus.

166 **FUNDING**

167 The work was partly supported by grants from Ministry of Science and Technology in Taiwan
168 (MOST 108-2314-B-182A-055, MOST109-2320-B-182A-015). The funders had no role in study
169 design, data collection and analysis, decision to publish, or preparation of the manuscript.

170 **TRANSPARENCY DECLARATION:** All authors declare no conflict of interest.

171

172 **REFERENCES**

- 173 1. Zhou W, Wang W, Wang H, Lu R, Tan W. First infection by all four non-severe acute
174 respiratory syndrome human coronaviruses takes place during childhood. *BMC Infect Dis*
175 2013;13:433
- 176 2. Gaunt ER, Hardie A, Claas ECJ, Simmonds P, Templeton KE. Epidemiology and clinical
177 presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3
178 years using a novel multiplex real-time PCR method. *J Clin Microbiol* 2010;48:2940–2947
- 179 3. Cui J, Li F, Shi Z-L. Origin and evolution of pathogenic coronaviruses. *Nat Rev Microbiol*
180 2019;17:181–192
- 181 4. Edridge AWD, Kaczorowska J, Hoste ACR, Bakker M, Klein M, Loens K, et al. Seasonal
182 coronavirus protective immunity is short-lasting. *Nat Med* 2020;26:1691–1693

- 183 5. Wu P-S, Chang L-Y, Berkhout B, Hoek L van der, Lu C-Y, Kao C-L, et al. Clinical
184 manifestations of human coronavirus NL63 infection in children in Taiwan. *Eur J Pediatr*
185 2008;167:75–80
- 186 6. Huang S-H, Su M-C, Tien N, Huang C-J, Lan Y-C, Lin C-S, et al. Epidemiology of human
187 coronavirus NL63 infection among hospitalized patients with pneumonia in Taiwan. *J*
188 *Microbiol Immunol Infect* 2017;50:763–70
- 189 7. Chen C-J, Lee P-I, Chang S-C, Huang Y-C, Chiu C-H, Hsieh Y-C, et al. Seroprevalence and
190 Severity of 2009 Pandemic Influenza A H1N1 in Taiwan.. *Plos One* 2011;6:e24440
- 191 8. Huang AT, Garcia-Carreras B, Hitchings MDT, Yang B, Katzelnick LC, Rattigan SM, et al. A
192 systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of
193 protection, and association with severity. *Nat Commun* 2020;11:4704
- 194 9. Lee, W. S., Wheatley, A. K., Kent, S. J. & DeKosky, B. J. Antibody-dependent enhancement and
195 SARS-CoV-2 vaccines and therapies. *Nat Microbiol* 2020;5,1185–91
- 196 10. Cloutier M, Nandi M, Ihsan AU, Chamard HA, Ilangumaran S, Ramanathan S. ADE and
197 hyperinflammation in SARS-CoV2 infection- comparison with dengue hemorrhagic fever and
198 feline infectious peritonitis. *Cytokine* 2020;136:155256

199

200

201 **Figure legend**

202 Figure 1. Neutralizing antibody (NAb) titers against human coronavirus 229E. (A) Distributions of
203 NAb titers in 200 Taiwanese at different ages. (B) Comparisons of geometric mean titers of NAb in
204 participants of six age groups. There was no significant difference among four age groups of
205 participants younger than 41 years old ($P > 0.1$ for all pairwise comparisons between the four
206 groups).

207

208 Table 1. Univariate and multivariate analysis of demographics and clinical features in 200 subjects
 209 with high and low neutralizing antibody titers against human coronavirus 229E in Taiwan

| Factor | Cases, N (%) | | | P value | |
|--------------------------------------|--------------------|----------------------------------|----------------------------------|------------|----------------------|
| | Total (n = 200) | High titer (≥ 10) (n = 39) | Low titer (< 10) (n = 161) | univariate | multivariate |
| Age in years | | | | | |
| (Mean ± SD) | 27.0 ± 24.8 | 64.3 ± 9.59 | 17.9 ± 18.0 | < .0001 | < .0001 [#] |
| 0-5 | 40 (20) | 0 (0) | 40 (24.8) | < .0001 | ... |
| 6-12 | 40 (20) | 0 (0) | 40 (24.8) | | |
| 13-18 | 40 (20) | 0 (0) | 40 (24.8) | | |
| 19-40 | 20 (10) | 0 (0) | 20 (12.4) | | |
| 41-60 | 20 (10) | 9 (23.1) | 11 (6.83) | | |
| > 60 | 40 (20) | 30 (76.9) | 10 (6.21) | | |
| Female gender | 123 (61.5) | 21 (53.8) | 102 (63.4) | .2736 | ... |
| Living area | | | | .0005 | |
| Taipei city | 33 (16.5) | 18 (46.2) | 15 (9.3) | | Referent |
| New Taipei city | 18 (9) | 2 (5.1) | 16 (9.9) | | .0455* |
| Taoyuan city | 68 (34) | 7 (17.9) | 61 (37.9) | | .1814 |
| Tainan city | 81 (40.5) | 12 (30.8) | 69 (42.9) | | .4266 |
| No. of family members (mean ± SD) | 4.59 ± 1.74 | 3.93 ± 1.65 | 4.73 ± 1.74 | .0234 | .8532 |
| Education level | | | | .3381 | ... |
| Non | 38 (19) | 4 (10.3) | 34 (21.1) | | |
| Primary | 47 (23.5) | 8 (20.5) | 39 (24.2) | | |

| | | | | | |
|------------------------------|-------------|-------------|-------------|--------|-------|
| Lower secondary | 31 (15.5) | 9 (23.1) | 22 (13.7) | | |
| Upper secondary | 36 (18) | 8 (20.5) | 28 (17.4) | | |
| Tertiary | 41 (20.5) | 10 (25.6) | 31 (19.2) | | |
| Comorbidity | | | | | |
| None | 181 (90.5) | 27 (69.2) | 154 (95.7) | .0001 | .8865 |
| Heart diseases | 8 (4) | 5 (12.8) | 3 (1.9) | .0240 | .9864 |
| Lung diseases | 4 (2) | 2 (5.1) | 2 (1.2) | .4802 | ... |
| Metabolic disorders | 5 (2.5) | 4 (10.3) | 1 (0.6) | .0372 | .9877 |
| Liver or kidney disorders | 3 (1.5) | 2 (5.1) | 1 (0.6) | .1950 | ... |
| Neurologic disorders | 1 (0.5) | 1 (2.6) | 0 (0.0) | .1950 | ... |
| Immune disorders | 1 (0.5) | 0 (0) | 1 (0.62) | 1.0000 | ... |
| pH1N1 | | | | | |
| HAI titers (mean ± SD) | 38.3 ± 39.3 | 26.7 ± 24.4 | 41.2 ± 41.7 | .0393 | ... |
| Seroprotection (HAI ≥ 40) | 72 (36) | 5 (12.8) | 67 (41.6) | .0008 | .7127 |
| Vaccination | 101 (50.5) | 16 (41.0) | 85 (52.8) | .1640 | ... |

210 Abbreviations: SD, standard deviation; HAI, hemagglutination-inhibition assay; pH1N1, pandemic

211 influenza A H1N1 in 2009

212 #Odds ratio 1.107 95% confidence interval 1.061–1.155

213 *Odds ratio 10.818 95% confidence interval .787–148.732

214

